Intracranial hemorrhage in patients with cancer treated with bevacizumab: The memorial Sloan-Kettering experience Journal Article
| Authors: | Khasraw, M.; Holodny, A.; Goldlust, S. A.; Deangelis, L. M. |
| Article Title: | Intracranial hemorrhage in patients with cancer treated with bevacizumab: The memorial Sloan-Kettering experience |
| Abstract: | Background: Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor approved for recurrent glioblastoma (GBM), metastatic breast, colorectal and non-small-cell lung cancers (NSCLC). There has been a potentially increased risk of intracranial hemorrhage (ICH) in patients receiving bevacizumab. Methods: We retrospectively identified patients with ICH who received bevacizumab between 1 January 2001 and 10 January 2009. Results: We identified 1024 patients with ICH, 4191 patients who received bevacizumab and 12 (0.3%) who met both our criteria. There were eight women and four men with a median age of 66 years. Primary cancers were ovarian (n = 3), NSCLC (n = 3), colon (n = 1), angiosarcoma (n = 1) and GBM (n = 4). Intracranial tumors were present in 9 of the 12 patients; the remaining three (25%) had no evidence of intracranial pathology. Two hundred and fifty-seven patients with these same primary pathologies and brain tumors were treated with bevacizumab; ICH was seen in nine (3.7%), which was comparable to the 3.6% frequency seen in comparable patients not receiving bevacizumab. Conclusions: ICH with bevacizumab treatment in this population is rare and does not appear to increase its frequency over the baseline rate of ICH in a comparable population. Most bevacizumab-related ICH occurs into central nervous system tumors but spontaneous hemorrhages were seen. © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. |
| Keywords: | controlled study; aged; major clinical study; bevacizumab; cancer patient; brain radiation; brain tumor; ovary cancer; lung non small cell cancer; incidence; deep vein thrombosis; angiosarcoma; retrospective study; risk assessment; colon cancer; glioblastoma; vascular endothelial growth factor; brain metastasis; brain hemorrhage; low molecular weight heparin; intracranial hemorrhage; primary brain tumors; metastatic brain tumors |
| Journal Title: | Annals of Oncology |
| Volume: | 23 |
| Issue: | 2 |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2012-01-01 |
| Start Page: | 458 |
| End Page: | 463 |
| Language: | English |
| DOI: | 10.1093/annonc/mdr148 |
| PROVIDER: | scopus |
| PUBMED: | 21543627 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 March 2012" - "CODEN: ANONE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
576De Angelis -
4Goldlust -
207Holodny -
10
Khasraw
Related MSK Work